Literature DB >> 12457150

Noninvasive assessment of cardiovascular risk: from Framingham to the future.

R A Vogel1, R M Benitez.   

Abstract

Risk assessment and risk factor modification have become essential tools in the management of cardiovascular disease. While the risk assessment defined by the Framingham Study researchers was a great leap forward, the search for additional and more precise markers of cardiovascular risk continues. Markers of thrombosis, abnormal endothelial function, plaque formation, and other events in atherosclerosis development are being evaluated. Some of the most promising for population screening are high-sensitivity C-reactive protein tests, degree of arterial stiffness (measured directly or as pulse pressure), and ankle-brachial index.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12457150

Source DB:  PubMed          Journal:  Rev Cardiovasc Med        ISSN: 1530-6550            Impact factor:   2.930


  4 in total

1.  Endothelial dysfunction, intima-media thickness, ankle-brachial pressure index, and pulse pressure in young post-myocardial infarction patients with various expressions of classical risk factors.

Authors:  Barbara Erzen; Miso Sabovic; Miran Sebestjen; Pavel Poredos
Journal:  Heart Vessels       Date:  2007-07-20       Impact factor: 2.037

Review 2.  Arterial stiffness in dialysis patients: where are we now?

Authors:  Mehmet Kanbay; Baris Afsar; Paul Gusbeth-Tatomir; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2009-11-19       Impact factor: 2.370

3.  The COSEVAST Study Outcome: Evidence of COVID-19 Severity Proportionate to Surge in Arterial Stiffness.

Authors:  Neeraj Kumar; Sanjeev Kumar; Abhyuday Kumar; Divendu Bhushan; Amarjeet Kumar; Ajeet Kumar; Veena Singh; Prabhat K Singh
Journal:  Indian J Crit Care Med       Date:  2021-10

Review 4.  "Smooth Muscle Cell Stiffness Syndrome"-Revisiting the Structural Basis of Arterial Stiffness.

Authors:  Nancy L Sehgel; Stephen F Vatner; Gerald A Meininger
Journal:  Front Physiol       Date:  2015-11-18       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.